source
- With new data, Regenxbio to seek FDA approval of Duchenne gene therapyThough two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA leadership will have a “mandate on rare disease flexibility.”BioPharma Dive · 2mo ago↗ source
- How Penn Medicine plans to use AI to train their doctorsPhysicians at Penn Medicine said they're thinking of how to use AI to train doctors. The idea came out of a $1.1 million grant Penn Medicine won in January through an education grant program with ...Endpoints · 2mo ago↗ source
- Biogen's anti-tau Alzheimer's drug misses Phase 2 goal, but claims signs of efficacyHere we go again? Biogen reported heavily anticipated Alzheimer’s data, saying its tau-targeting drug BIIB080 missed its primary endpoint in a Phase 2 study but slowed patients’ clinical decline at…